drugset / Trial / NCT00810485
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the effect of ADX10059 in patients with gastroesophageal reflux disease who are partial responders to proton pump inhibitors
Timeline
- Start
- 2008-12
- Primary completion
- 2009-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RASEGLURANT | Small molecule | 50 mg | Oral |
| Subject | RASEGLURANT | Small molecule | 100 mg | Oral |
| Subject | RASEGLURANT | Small molecule | 150 mg | Oral |